Investor Relations
We are advancing a new approach to drug creation—one grounded in the ability to design proteins with defined biological intent.
By integrating machine learning with large-scale experimentation, this approach aims to reduce the uncertainty, time, and cost associated with developing protein-based medicines.
Shown here, GB-0895 is designed to bind TSLP with ultra-high affinity, neutralizing downstream inflammatory signaling in airway disease. Optimized for an extended half-life, it is currently in two global Phase 3 studies for severe asthma, with twice-yearly subcutaneous dosing under evaluation, and in a Phase 1 study in COPD.
This is Generate.
We are a clinical-stage generative biology company pioneering the AI revolution in drug design and development.
Founded in 2018, we are advancing a growing pipeline of clinical and preclinical programs across multiple disease areas and protein modalities.
By unifying computational design and clinical development within a single operating model, we translate this approach into clinical-stage programs and are leading a shift from traditional drug discovery toward systematic drug generation.